Triple Therapy With Tegoprazan in H. Pylori Positive Patients
Status:
Completed
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The current study is designed to demonstrate the non-inferiority of tegoprazan triple therapy
(tegoprazan, amoxicillin, and clarithromycin; hereinafter TAC) to lansoprazole triple therapy
(lansoprazole, amoxicillin, and clarithromycin; hereinafter LAC) in terms of H. pylori
eradication rate and to evaluate the safety of tegoprazan after oral administration of the
therapy for 7 days, twice daily in H. pylori positive patients.